Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs
(NASDAQ:PPCB), MELBOURNE, Australia, Dec. 04, 2025 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic diseases such as recurrent and metastatic cancer, today announced plans to investigate the phenomenon of “mesenchymal drift”–an emerging area of research that may help unlock the mechanisms behind the […]